NK cell therapy for pancreatic cancer after standard treatment
Part of Cancer clinical trials.
This trial tests a new therapy using your own immune cells (NK cells) that are specially trained to find and attack cancer cells. It is for people with pancreatic cancer that has not responded to previous treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have a type of pancreatic cancer (pancreatic ductal adenocarcinoma or IPMN carcinosis) that has worsened after at least one previous treatment.
- You are well enough to get out of bed and care for yourself (ECOG score 0-2).
- You have at least one tumor that can be measured on a scan.
- You do not have active infections like HIV, hepatitis B, hepatitis C, or tuberculosis.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new treatment where CAR-NK cells are injected directly into the pancreatic tumor using an endoscope. It is designed for people with advanced pancreatic cancer that has come back or cannot be removed by surgery.
This trial tests a new treatment using immune cells (CAR-NK cells) to fight pancreatic cancer that has spread or come back. It may be an option if standard treatments have stopped working, were not tolerated, or were refused.
This trial tests a new type of immunotherapy called CAR-NK cells (CL-NK-001) for patients with advanced pancreatic cancer that has a specific marker (eGR1). The goal is to see if these specially grown natural killer cells can attack the cancer after standard treatments have stopped working.
This trial tests a new type of immune cell therapy called CAR-NK cells that target two proteins (MSLN and MUC1) often found on pancreatic cancer cells. It is for people whose cancer has spread or cannot be removed, and who have already tried at least one standard treatment.
This trial tests a new type of immune cell therapy called iNKT cells for people with advanced pancreatic cancer that has not responded to standard treatments. The cells are from a healthy donor and may help your immune system fight the cancer.
This trial tests whether adding natural killer (NK) cell therapy to standard chemotherapy after surgery can help prevent pancreatic or bile duct cancer from coming back. It is for patients who have had their tumor completely removed and are now ready for adjuvant chemotherapy.
Hear when a new Pancreatic Cancer Non-resectable trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.